TMEM161B

Across TCGA pan-cancer cohorts, TMEM161B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM161B data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM161B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM161B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD and GBM are the cancer types where TMEM161B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.891	0.394	.011	6	view →
GBM	OS	Median	All	0.602	0.353	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMEM161B–LUAD (DFS)

Open the LUAD breakdown →